GLIX1 Shows Dose-Dependent GBM Tumor Inhibition, Outperforms Temozolomide in Resistant Model
GLIX1 showed significant tumor growth inhibition and survival benefit in three orthotopic CDX glioblastoma models, with robust dose-dependent efficacy even at the lowest doses tested. In a temozolomide-resistant patient-derived xenograft model, GLIX1 produced a potent anti-tumor effect while temozolomide showed no efficacy.
1. Preclinical Efficacy of GLIX1
Orally administered GLIX1 demonstrated robust anti-tumor activity in three orthotopic cell-derived xenograft glioblastoma models, producing significant tumor growth inhibition and survival benefit across all tested doses. In a subcutaneous patient-derived xenograft model resistant to temozolomide, GLIX1 induced a strong anti-tumor response while temozolomide showed no effect, highlighting its potential against treatment-resistant GBM.
2. Clinical Development Plans
A Phase 1/2a open-label, multicenter trial is evaluating GLIX1 as monotherapy in up to 30 patients with recurrent and progressive GBM and other high-grade gliomas to establish a maximum tolerated dose and assess safety, PK/PD and preliminary efficacy. Trial updates are expected in the second half of 2026, with full dose escalation results anticipated in 2027, followed by expansion cohorts including newly diagnosed GBM and combination regimens.